Financhill
Sell
11

CATX Quote, Financials, Valuation and Earnings

Last price:
$3.05
Seasonality move :
15.07%
Day range:
$3.13 - $3.29
52-week range:
$2.70 - $19.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.96x
P/B ratio:
0.65x
Volume:
416K
Avg. volume:
973K
1-year change:
-65.12%
Market cap:
$212.2M
Revenue:
--
EPS (TTM):
-$1.46

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CATX
Perspective Therapeutics
$297.8K -$0.25 -- -40.08% $15.61
ALUR
Allurion Technologies
$5.6M -$5.76 -22.23% -38.6% $28.67
RVP
Retractable Technologies
-- -- -- -- --
VNRX
VolitionRX
$545.3K -$0.05 115.19% -54.55% $3.34
VTAK
Catheter Precision
$280K -$0.20 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$31.8M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CATX
Perspective Therapeutics
$3.14 $15.61 $212.2M -- $0.00 0% 16.96x
ALUR
Allurion Technologies
$5.04 $28.67 $13.7M -- $0.00 0% 0.30x
RVP
Retractable Technologies
$0.82 -- $24.4M -- $0.00 0% 0.64x
VNRX
VolitionRX
$0.59 $3.34 $54.3M -- $0.00 0% 37.82x
VTAK
Catheter Precision
$0.37 -- $3M 0.42x $0.00 0% 0.99x
XTNT
Xtant Medical Holdings
$0.59 -- $81.4M -- $0.00 0% 0.68x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CATX
Perspective Therapeutics
-- -3.617 -- --
ALUR
Allurion Technologies
-125.75% -5.404 91.46% 2.01x
RVP
Retractable Technologies
1.55% 0.025 11.72% 5.80x
VNRX
VolitionRX
-28.76% -0.702 8.83% 0.19x
VTAK
Catheter Precision
12% -1.817 128.21% 0.53x
XTNT
Xtant Medical Holdings
43.2% 0.590 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
ALUR
Allurion Technologies
$3.1M -$12.3M -- -- -166.48% -$11.5M
RVP
Retractable Technologies
-$14.8K -$5.1M -16.57% -16.83% -18.58% -$6.5M
VNRX
VolitionRX
-- -$5.8M -- -- -1217.88% -$5.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

Perspective Therapeutics vs. Competitors

  • Which has Higher Returns CATX or ALUR?

    Allurion Technologies has a net margin of -- compared to Perspective Therapeutics's net margin of -167.77%. Perspective Therapeutics's return on equity of -- beat Allurion Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CATX
    Perspective Therapeutics
    -- -$0.21 --
    ALUR
    Allurion Technologies
    57.97% -$0.14 -$28.7M
  • What do Analysts Say About CATX or ALUR?

    Perspective Therapeutics has a consensus price target of $15.61, signalling upside risk potential of 411.15%. On the other hand Allurion Technologies has an analysts' consensus of $28.67 which suggests that it could grow by 468.78%. Given that Allurion Technologies has higher upside potential than Perspective Therapeutics, analysts believe Allurion Technologies is more attractive than Perspective Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CATX
    Perspective Therapeutics
    7 1 0
    ALUR
    Allurion Technologies
    2 1 0
  • Is CATX or ALUR More Risky?

    Perspective Therapeutics has a beta of 1.220, which suggesting that the stock is 22.033% more volatile than S&P 500. In comparison Allurion Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CATX or ALUR?

    Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allurion Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Allurion Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CATX or ALUR?

    Perspective Therapeutics quarterly revenues are --, which are smaller than Allurion Technologies quarterly revenues of $5.4M. Perspective Therapeutics's net income of -$15.1M is lower than Allurion Technologies's net income of -$9M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Allurion Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 16.96x versus 0.30x for Allurion Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CATX
    Perspective Therapeutics
    16.96x -- -- -$15.1M
    ALUR
    Allurion Technologies
    0.30x -- $5.4M -$9M
  • Which has Higher Returns CATX or RVP?

    Retractable Technologies has a net margin of -- compared to Perspective Therapeutics's net margin of -18.58%. Perspective Therapeutics's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    CATX
    Perspective Therapeutics
    -- -$0.21 --
    RVP
    Retractable Technologies
    -0.14% -$0.07 $84.8M
  • What do Analysts Say About CATX or RVP?

    Perspective Therapeutics has a consensus price target of $15.61, signalling upside risk potential of 411.15%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Perspective Therapeutics has higher upside potential than Retractable Technologies, analysts believe Perspective Therapeutics is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    CATX
    Perspective Therapeutics
    7 1 0
    RVP
    Retractable Technologies
    0 0 0
  • Is CATX or RVP More Risky?

    Perspective Therapeutics has a beta of 1.220, which suggesting that the stock is 22.033% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.958, suggesting its more volatile than the S&P 500 by 95.763%.

  • Which is a Better Dividend Stock CATX or RVP?

    Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

  • Which has Better Financial Ratios CATX or RVP?

    Perspective Therapeutics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Perspective Therapeutics's net income of -$15.1M is lower than Retractable Technologies's net income of -$1.9M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 16.96x versus 0.64x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CATX
    Perspective Therapeutics
    16.96x -- -- -$15.1M
    RVP
    Retractable Technologies
    0.64x -- $10.3M -$1.9M
  • Which has Higher Returns CATX or VNRX?

    VolitionRX has a net margin of -- compared to Perspective Therapeutics's net margin of -1226.82%. Perspective Therapeutics's return on equity of -- beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CATX
    Perspective Therapeutics
    -- -$0.21 --
    VNRX
    VolitionRX
    -- -$0.07 -$17.8M
  • What do Analysts Say About CATX or VNRX?

    Perspective Therapeutics has a consensus price target of $15.61, signalling upside risk potential of 411.15%. On the other hand VolitionRX has an analysts' consensus of $3.34 which suggests that it could grow by 469.97%. Given that VolitionRX has higher upside potential than Perspective Therapeutics, analysts believe VolitionRX is more attractive than Perspective Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CATX
    Perspective Therapeutics
    7 1 0
    VNRX
    VolitionRX
    2 1 0
  • Is CATX or VNRX More Risky?

    Perspective Therapeutics has a beta of 1.220, which suggesting that the stock is 22.033% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.200, suggesting its more volatile than the S&P 500 by 20.035%.

  • Which is a Better Dividend Stock CATX or VNRX?

    Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CATX or VNRX?

    Perspective Therapeutics quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $474.5K. Perspective Therapeutics's net income of -$15.1M is lower than VolitionRX's net income of -$5.8M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 16.96x versus 37.82x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CATX
    Perspective Therapeutics
    16.96x -- -- -$15.1M
    VNRX
    VolitionRX
    37.82x -- $474.5K -$5.8M
  • Which has Higher Returns CATX or VTAK?

    Catheter Precision has a net margin of -- compared to Perspective Therapeutics's net margin of -4291.67%. Perspective Therapeutics's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    CATX
    Perspective Therapeutics
    -- -$0.21 --
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About CATX or VTAK?

    Perspective Therapeutics has a consensus price target of $15.61, signalling upside risk potential of 411.15%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 437.35%. Given that Catheter Precision has higher upside potential than Perspective Therapeutics, analysts believe Catheter Precision is more attractive than Perspective Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CATX
    Perspective Therapeutics
    7 1 0
    VTAK
    Catheter Precision
    0 0 0
  • Is CATX or VTAK More Risky?

    Perspective Therapeutics has a beta of 1.220, which suggesting that the stock is 22.033% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.108, suggesting its less volatile than the S&P 500 by 110.771%.

  • Which is a Better Dividend Stock CATX or VTAK?

    Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CATX or VTAK?

    Perspective Therapeutics quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $96K. Perspective Therapeutics's net income of -$15.1M is lower than Catheter Precision's net income of -$4.1M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 16.96x versus 0.99x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CATX
    Perspective Therapeutics
    16.96x -- -- -$15.1M
    VTAK
    Catheter Precision
    0.99x 0.42x $96K -$4.1M
  • Which has Higher Returns CATX or XTNT?

    Xtant Medical Holdings has a net margin of -- compared to Perspective Therapeutics's net margin of -17.98%. Perspective Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    CATX
    Perspective Therapeutics
    -- -$0.21 --
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About CATX or XTNT?

    Perspective Therapeutics has a consensus price target of $15.61, signalling upside risk potential of 411.15%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 284.09%. Given that Perspective Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Perspective Therapeutics is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    CATX
    Perspective Therapeutics
    7 1 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is CATX or XTNT More Risky?

    Perspective Therapeutics has a beta of 1.220, which suggesting that the stock is 22.033% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.871%.

  • Which is a Better Dividend Stock CATX or XTNT?

    Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CATX or XTNT?

    Perspective Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Perspective Therapeutics's net income of -$15.1M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 16.96x versus 0.68x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CATX
    Perspective Therapeutics
    16.96x -- -- -$15.1M
    XTNT
    Xtant Medical Holdings
    0.68x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock